IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 5, 2008
Grant Date -
May 29, 2003
app pub date -
Sep 10, 2002
filing date -
Sep 11, 2001
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention relates to feline IGF-1, to the nucleotide sequence encoding this protein and to the use of IGF-1 as adjuvant for the vaccination of cats, in particular against the feline retroviruses FIV and FeLV. IGF-1 may be used in the form of protein or may be expressed in vivo by a suitable, e.g. viral or plasmid, expression vector. The invention relates to all types of vaccines, namely inactivated, attenuated, sub-unit and recombinant vaccines. The vectors expressing IGF-1 in vivo may also be used in immunity-stimulating compositions.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully